JP2019500894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500894A5 JP2019500894A5 JP2018543279A JP2018543279A JP2019500894A5 JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5 JP 2018543279 A JP2018543279 A JP 2018543279A JP 2018543279 A JP2018543279 A JP 2018543279A JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- variant
- seq
- domain
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 25
- 230000004048 modification Effects 0.000 claims 25
- 238000012986 modification Methods 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 12
- 230000000139 costimulatory effect Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021133074A JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251052P | 2015-11-04 | 2015-11-04 | |
| US62/251,052 | 2015-11-04 | ||
| PCT/US2016/060724 WO2017079694A2 (en) | 2015-11-04 | 2016-11-04 | Chimeric antigen receptors targeting her2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Division JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500894A JP2019500894A (ja) | 2019-01-17 |
| JP2019500894A5 true JP2019500894A5 (OSRAM) | 2019-12-19 |
| JP6932709B2 JP6932709B2 (ja) | 2021-09-08 |
Family
ID=58662864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543279A Expired - Fee Related JP6932709B2 (ja) | 2015-11-04 | 2016-11-04 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11197919B2 (OSRAM) |
| EP (2) | EP3371227B8 (OSRAM) |
| JP (3) | JP6932709B2 (OSRAM) |
| KR (1) | KR20180083874A (OSRAM) |
| CN (2) | CN108779174B (OSRAM) |
| AU (2) | AU2016349722A1 (OSRAM) |
| BR (1) | BR112018009129A2 (OSRAM) |
| CA (1) | CA3004306A1 (OSRAM) |
| ES (1) | ES2909973T3 (OSRAM) |
| IL (2) | IL259120B (OSRAM) |
| MX (2) | MX2018005674A (OSRAM) |
| RU (1) | RU2753695C2 (OSRAM) |
| WO (1) | WO2017079694A2 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| CN108779174B (zh) * | 2015-11-04 | 2022-11-29 | 希望之城公司 | 靶向her2的嵌合抗原受体 |
| KR20180105709A (ko) | 2016-02-05 | 2018-09-28 | 시티 오브 호프 | 중추 신경계의 암의 치료를 위한 조작된 t 세포의 투여 |
| WO2018102761A1 (en) * | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| EP3579848B1 (en) | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| SG11201908337VA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| JP7386796B2 (ja) * | 2017-11-14 | 2023-11-27 | グリーン クロス ラボ セル コーポレーション | 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体 |
| CN109608547B (zh) * | 2017-12-29 | 2022-03-15 | 郑州大学第一附属医院 | 表达Her2的嵌合抗原受体、慢病毒表达载体及其应用 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| JP2021512614A (ja) * | 2018-02-09 | 2021-05-20 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における接着受容体構築物及びその使用 |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019157461A1 (en) * | 2018-02-11 | 2019-08-15 | The Regents Of The University Of California | Car-t cells and autoimmune diseases |
| SG10201801219VA (en) * | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2019222579A1 (en) * | 2018-05-17 | 2019-11-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| KR102839381B1 (ko) | 2018-08-29 | 2025-07-28 | 내셔널 유니버시티 오브 싱가포르 | 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2020191336A1 (en) | 2019-03-21 | 2020-09-24 | Yamaguchi, Yukiko | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| AU2020268372A1 (en) * | 2019-05-07 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| KR20220153578A (ko) * | 2020-01-23 | 2022-11-18 | 엑수마 바이오테크, 코포레이션 | Her2에 대한 키메라 항원 수용체 및 이의 사용 방법 |
| AR122018A1 (es) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| WO2021235894A1 (en) * | 2020-05-22 | 2021-11-25 | Green Cross Lab Cell Corporation | Anti-HER2 Antibody or Antigen-binding Fragment thereof, and Chimeric Antigen Receptor Comprising Same |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| WO2022187182A1 (en) * | 2021-03-02 | 2022-09-09 | The Trustees Of The University Of Pennsylvania | Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| US20240366662A1 (en) | 2021-03-30 | 2024-11-07 | City Of Hope | Car t cell therapy and ifn gamma |
| CN117642510A (zh) * | 2021-07-01 | 2024-03-01 | 宁波茂行生物医药科技有限公司 | 靶向her2的通用型car-t细胞及其制备方法 |
| JP2024528038A (ja) | 2021-07-29 | 2024-07-26 | ソノマ バイオセラピューティクス， インコーポレイテッド | 調節性ｔ細胞を標的として自己免疫疾患を処置するための滑膜細胞外マトリックス特異的キメラ抗原受容体 |
| US20240374722A1 (en) * | 2021-08-24 | 2024-11-14 | Cells & Genes Biotech (Shanghai) Co., Ltd | T cell product and use thereof |
| CN116023491A (zh) | 2021-10-25 | 2023-04-28 | 江苏众红生物工程创药研究院有限公司 | 抗cd26抗体及其应用 |
| WO2023172514A1 (en) * | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| KR20240157693A (ko) | 2022-03-10 | 2024-11-01 | 시티 오브 호프 | 세포 면역요법을 위한 막-결합 il-12 |
| EP4504799A1 (en) | 2022-04-08 | 2025-02-12 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| IL316101A (en) * | 2022-04-08 | 2024-12-01 | Fate Therapeutics Inc | Skeletal cells refer to solid tumors and their use |
| CN114805584B (zh) * | 2022-06-30 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗原结合蛋白及其用途 |
| AU2024264153A1 (en) | 2023-04-27 | 2025-11-13 | Vanudis GmbH | Coreceptor chimeric antigen receptor |
| US20250146017A1 (en) | 2023-11-06 | 2025-05-08 | City Of Hope | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers |
| CN117924518B (zh) * | 2024-01-05 | 2025-08-22 | 苏州艾凯利元生物科技有限公司 | 用于nk细胞的嵌合抗原受体及工程化的nk细胞 |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2308981T3 (es) * | 1999-04-09 | 2008-12-16 | Universitat Zurich | Metodo para la estabilizacion de las inmunoglobulinas hibridas o fragmentos de inmunoglobulina y fragmentos anti-egp-2-scfv estabilizado. |
| RS53594B1 (sr) * | 2004-07-22 | 2015-02-27 | Genentech, Inc. | Preparat her2 antitela |
| KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| DK2496698T3 (en) * | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| JP2013531474A (ja) * | 2010-04-30 | 2013-08-08 | エスペランス ファーマシューティカルズ， インコーポレイテッド | 溶解性ペプチド−Ｈｅｒ２／ｎｅｕ（ヒト上皮成長因子レセプター２）リガンド結合体およびその使用方法 |
| US8491908B2 (en) * | 2010-06-01 | 2013-07-23 | Canon Kabushiki Kaisha | Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| JP6141834B2 (ja) * | 2011-06-06 | 2017-06-07 | ノヴォ ノルディスク アー／エス | 治療抗体 |
| IL293944A (en) * | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| JP6306596B2 (ja) | 2012-10-04 | 2018-04-04 | リサーチ ディベロップメント ファウンデーション | セリンプロテアーゼ分子および療法 |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| IL238323B2 (en) * | 2012-10-30 | 2023-11-01 | Esperance Pharmaceuticals Inc | Antibody/drug conjugates and methods of use |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| WO2015028444A1 (en) * | 2013-08-26 | 2015-03-05 | Universität Zu Köln | Anti cd30 chimeric antigen receptor and its use |
| ES2767423T3 (es) * | 2014-01-13 | 2020-06-17 | Hope City | Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso |
| CN106459924A (zh) * | 2014-04-23 | 2017-02-22 | 得克萨斯州大学系统董事会 | 用于疗法中的嵌合抗原受体(car)及其制备方法 |
| CN108779174B (zh) * | 2015-11-04 | 2022-11-29 | 希望之城公司 | 靶向her2的嵌合抗原受体 |
-
2016
- 2016-11-04 CN CN201680076412.0A patent/CN108779174B/zh not_active Expired - Fee Related
- 2016-11-04 JP JP2018543279A patent/JP6932709B2/ja not_active Expired - Fee Related
- 2016-11-04 WO PCT/US2016/060724 patent/WO2017079694A2/en not_active Ceased
- 2016-11-04 CA CA3004306A patent/CA3004306A1/en active Pending
- 2016-11-04 EP EP16863128.1A patent/EP3371227B8/en active Active
- 2016-11-04 RU RU2018118817A patent/RU2753695C2/ru active
- 2016-11-04 CN CN202211409883.2A patent/CN116063574A/zh active Pending
- 2016-11-04 BR BR112018009129-4A patent/BR112018009129A2/pt active Search and Examination
- 2016-11-04 AU AU2016349722A patent/AU2016349722A1/en not_active Abandoned
- 2016-11-04 EP EP22157943.6A patent/EP4074731A1/en not_active Withdrawn
- 2016-11-04 KR KR1020187015769A patent/KR20180083874A/ko not_active Ceased
- 2016-11-04 ES ES16863128T patent/ES2909973T3/es active Active
- 2016-11-04 US US15/773,754 patent/US11197919B2/en active Active
- 2016-11-04 MX MX2018005674A patent/MX2018005674A/es unknown
-
2018
- 2018-05-03 IL IL259120A patent/IL259120B/en unknown
- 2018-05-04 MX MX2022013498A patent/MX2022013498A/es unknown
-
2021
- 2021-08-18 JP JP2021133074A patent/JP7264954B2/ja active Active
- 2021-12-06 US US17/543,148 patent/US20220265796A1/en not_active Abandoned
-
2022
- 2022-01-10 AU AU2022200116A patent/AU2022200116A1/en not_active Abandoned
- 2022-04-13 IL IL292222A patent/IL292222A/en unknown
-
2023
- 2023-04-13 JP JP2023065384A patent/JP2023100653A/ja not_active Withdrawn
-
2024
- 2024-10-18 US US18/919,692 patent/US20250333471A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500894A5 (OSRAM) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| JP2017537627A5 (OSRAM) | ||
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| CN106536563B (zh) | 嵌合抗原受体 | |
| Park et al. | Treating cancer with genetically engineered T cells | |
| ES2959480T3 (es) | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo | |
| ES2848478T3 (es) | Receptores quiméricos para antígenos y usos de estos | |
| CN104379599B (zh) | 能用于过继性细胞疗法的多肽 | |
| JP2017500869A5 (OSRAM) | ||
| JP2019528078A (ja) | 細胞治療のための構造的に活性なサイトカイン受容体 | |
| RU2016143384A (ru) | Трансгенные генетические метки и способы применения | |
| JP2016520074A5 (OSRAM) | ||
| JP2018509163A5 (OSRAM) | ||
| JP2016538855A5 (OSRAM) | ||
| CN108779160A (zh) | 施用工程化t细胞以治疗中枢神经系统中的癌症 | |
| JP2017538401A5 (OSRAM) | ||
| JPWO2020014366A5 (OSRAM) | ||
| Wang et al. | Minicircle DNA-mediated CAR T cells targeting CD44 suppressed hepatocellular carcinoma both in vitro and in vivo | |
| JP2019512251A5 (OSRAM) |